News

The approved label includes both complicated skin and skin structure infections caused by certain gram positive infections, at an approved dose of 4 mg/kg, and bloodstream infections, including

Progen said the overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that

Pharmacopeia will receive a $1 million milestone payment from Schering-Plough as a result of this trial initiation. Les Browne, president and CEO of Pharmacopeia, said: “The Schering-Plough collaboration

Encysive has been discussing possible protocols for the trial, to be called Stride 5, with its scientific advisory board and other experts. The company will now work with

Intronn is known for developing and patenting spliceosome-mediated RNA trans-splicing (SMaRT) technology, a new approach to genetic medicine. SMaRT RNA therapy uses gene therapy vectors to deliver proprietary

InterMune has also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock. All of the shares in the offering are

The fast track program is designed to facilitate the development and expedite the regulatory review of new drugs that demonstrate the potential to treat serious or life-threatening diseases

The positive opinion for Eucreas was issued by the Committee for Medicinal Products for Human Use (CHMP), which reviews medicines for the European Commission (EC). The recommendation was

The European Commission generally follows the recommendations of the committee for medicinal products for human use (CHMP) and delivers its final decision within three months. The decision will